Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.  Our lead asset, LP352, is an oral, centrally acting, 5-HT2c superagonist in development for the potential treatment of developmental and epileptic encephalopathies (DEEs) such as Dravet syndrome, Lennox-Gastaut syndrome (LGS) and other epileptic disorders.

LP352 has novel chemistry and attributes, and was designed to be more specific and selective for the 5-HT2c receptor subtype, giving it the potential to reduce seizures in DEE patients while overcoming the known or perceived safety limitations of available drugs in the 5-HT2 class.  There is real world clinical evidence supporting the use of 5-HT2c agonism for the treatment of seizures associated with Dravet syndrome.

We are currently in a Phase 1 multiple ascending dose study and plan to initiate a Phase 1b/2a placebo-controlled, basket study in patients with DEEs in the first quarter of 2021.  In the Phase 1b/2a study we plan to initially enroll adult participants with DEEs including Dravet syndrome with the goal of including younger participants as we gather additional data.  For more information about the study or how to participate, please contact [email protected].

At Longboard, we are committed to our goal of developing medicines for neurological diseases, with a focus for LP352 in severe epilepsies.